Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354170 · ClinicalTrials.gov registry record · Phase 2
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
A Phase 2 study of Central Serous Chorioretinopathy, sponsored by Roger Goldberg, M.D., MBA.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT02354170 is a Phase 2 study of Central Serous Chorioretinopathy that has completed, run by Roger Goldberg, M.D., MBA. The registered enrollment target is 16 participants, below the 86-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02354170, a Phase 2 study of Central Serous Chorioretinopathy, has completed, sponsored by Roger Goldberg, M.D., MBA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mifepristone
Study Locations (2)
California
- Bay Area Retina Associates - Walnut Creek
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354170
The ClinicalTrials.gov registry entry for NCT02354170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (81% lower). The listed sponsor is Roger Goldberg, M.D., MBA, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02354170 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02354170 about?
NCT02354170 is a clinical study titled "Short-Term Oral Mifepristone for Central Serous Chorioretinopathy". The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.
What is the current status of trial NCT02354170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-01. Estimated completion is 2017-04-27.
What conditions does trial NCT02354170 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT02354170?
The interventions under investigation include: Placebo (DRUG), Mifepristone (DRUG).
Who is sponsoring clinical trial NCT02354170?
This trial is sponsored by Roger Goldberg, M.D., MBA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02354170 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.